Avantor Receivables 2018-2025 | AVTR

Avantor receivables for the quarter ending March 31, 2025 were $1.096B, a 2.96% decline year-over-year.

  • Avantor receivables for 2024 were $1.035B, a 10.06% decline from 2023.
  • Avantor receivables for 2023 were $1.15B, a 5.6% decline from 2022.
  • Avantor receivables for 2022 were $1.218B, a 0.3% decline from 2021.

Avantor Receivables 2018-2025 | AVTR

  • Avantor receivables for 2024 were $1.035B, a 10.06% decline from 2023.
  • Avantor receivables for 2023 were $1.15B, a 5.6% decline from 2022.
  • Avantor receivables for 2022 were $1.218B, a 0.3% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.1B
CVS Health (CVS)$76.8B
Elevance Health (ELV)$65.1B
Cencora (COR)$56.3B
DiDi Global (DIDIY)$25.7B
Labcorp Holdings (LH)$22.2B
Natera (NTRA)$19B
BioMerieux (BMXMF)$17.7B
EUROFINS SCIENT (ERFSF)$15.9B
ICON (ICLR)$15.1B
CochLear (CHEOY)$13.4B
Solventum (SOLV)$12.9B
Medpace Holdings (MEDP)$12.6B
Revvity (RVTY)$12.2B
Viatris (VTRS)$11B
Sonic Healthcare (SKHHY)$9.1B
Charles River Laboratories (CRL)$8.7B
HealthEquity (HQY)$8.3B
Caris Life Sciences,�Inc (CAI)$7.5B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$5.1B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.5B
Surgery Partners (SGRY)$2.7B
Organon (OGN)$2.7B
Concentras Parent (CON)$2.5B
Alignment Healthcare (ALHC)$2.3B
GeneDx Holdings (WGS)$2.3B
Progyny (PGNY)$2B
GoodRx Holdings (GDRX)$1.8B